European Society of Cardiology Congress 2016
- Authors: - -
- Issue: Vol 18, No 12 (2016)
- Pages: 127-128
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94701
- ID: 94701
Cite item
Full Text
Abstract
Новые данные обширной исследовательской программы и результаты исследований реальной клинической практики из разных стран вновь подтвердили высокую эффективность и благоприятный профиль безопасности ривароксабана (Ксарелто®) компании Bayer
Full Text
##article.viewOnOriginalSite##References
- Lip G.Y.H, Hammerstingl C, Marin F et al. Left Atrial Thrombus Resolution in Atrial Fibrillation or Flutter: Results of a Prospective Study with Rivaroxaban (X-TRA) and a Retrospective Observational Registry Providing Baseline Data (CLOT-AF). Am Heart J 2016; 178: 126-34.
- Ikeda T et al. XAPASS: Evidence of Safety and Effectiveness in Japanese Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation under Real - World Clinical Practice. Oral Presentation at ESC Congress 2016.
- Leif Friberg. Major Bleeding among Patients with Atrial Fibrillation treated with Rivaroxaban or Warfarin in Sweden. Poster Presentation at ESC Congress 2016.
- Coleman C et al. Real - world evidence of stroke prevention in patients with non - valvular atrial fibrillation in the United States: the REVISIT-US study. Poster Presentation at ESC Congress 2016.
- Hori M, Matsumoto M, Tanahashi N et al. Rivaroxaban vs. Warfarin in Japanese Patients with Atrial Fibrillation - The J-ROCKET AF Study. Circulation 2012; 76 (9): 2104-11.
- Patel M.R, Mahaffey K.W, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation NEJM 2011; 365: 883-91.
- Coleman C.I et al. Real - world EVIdence on Stroke prevention In patients with aTrial Fibrillation in the United States (REVISIT-US) [Presentation at ECAS 2016] Available at: http://clinicaltrialresults.org/Slides/REVISIT_US_Slides.pptx
